Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$67.33 USD

67.33
6,875,313

-0.09 (-0.13%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $67.32 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BSX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Boston Scientific Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 865 928 1,925 1,734 217
Receivables 2,228 1,970 1,778 1,531 1,828
Notes Receivable 0 0 0 0 0
Inventories 2,484 1,867 1,610 1,351 1,579
Other Current Assets 936 995 1,004 2,078 1,075
Total Current Assets 6,514 5,760 6,317 6,694 4,699
Net Property & Equipment 2,859 2,446 2,252 2,084 2,079
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 3,841 3,942 4,142 4,210 4,196
Intangibles 20,390 18,822 18,109 15,868 18,062
Deposits & Other Assets 1,531 1,500 1,410 1,921 1,529
Total Assets 35,136 32,469 32,229 30,777 30,565
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 1,416
Accounts Payable 942 862 794 513 542
Current Portion Long-Term Debt 531 20 261 13 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,646 2,160 2,436 2,197 2,109
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 814 761 783 958 800
Total Current Liabilities 4,933 3,803 4,274 3,681 4,866
Mortgages 0 0 0 0 0
Deferred Taxes/Income 134 144 310 330 595
Convertible Debt 0 0 0 0 0
Long-Term Debt 8,571 8,915 8,804 9,130 8,592
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,967 2,035 2,220 2,309 2,635
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 15,606 14,896 15,607 15,451 16,688
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 17 17 17 17 16
Capital Surplus 20,647 20,289 19,986 19,732 17,561
Retained Earnings 819 -750 -1,392 -2,378 -2,253
Other Equity 297 269 263 207 270
Treasury Stock 2,251 2,251 2,251 2,251 1,717
Total Shareholder's Equity 19,530 17,573 16,622 15,326 13,877
Total Liabilities & Shareholder's Equity 35,136 32,469 32,229 30,777 30,565
Total Common Equity 19,530 17,573 16,622 15,326 13,877
Shares Outstanding 1,464.90 1,432.30 1,424.90 1,417.10 1,393.80
Book Value Per Share 13.33 12.27 11.67 10.82 9.96

Fiscal Year End for Boston Scientific Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 865 952 426 570
Receivables NA 2,228 2,101 2,134 2,076
Notes Receivable NA 0 0 0 0
Inventories NA 2,484 2,404 2,250 2,050
Other Current Assets NA 936 1,048 1,076 1,007
Total Current Assets NA 6,514 6,504 5,886 5,704
Net Property & Equipment NA 2,859 2,635 2,534 2,478
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 3,841 3,840 3,865 3,900
Intangibles NA 20,390 19,457 19,722 19,329
Deposits & Other Assets NA 1,531 1,605 1,595 1,482
Total Assets NA 35,136 34,043 33,601 32,892
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 942 929 899 868
Current Portion Long-Term Debt NA 531 513 559 510
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 2,646 2,255 2,164 1,918
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 814 882 940 787
Total Current Liabilities NA 4,933 4,579 4,562 4,083
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 134 91 135 210
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 8,571 8,386 8,494 8,495
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1,858 1,926 1,995
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 15,606 14,914 15,116 14,783
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 17 17 17 17
Capital Surplus NA 20,647 20,573 20,441 20,356
Retained Earnings NA 819 315 -189 -450
Other Equity NA 297 474 467 437
Treasury Stock NA 2,251 2,251 2,251 2,251
Total Shareholder's Equity NA 19,530 19,129 18,485 18,109
Total Liabilities & Shareholder's Equity NA 35,136 34,043 33,601 32,892
Total Common Equity 0 19,530 19,129 18,485 18,109
Shares Outstanding 1,467.10 1,464.90 1,464.20 1,400.00 1,434.70
Book Value Per Share 0.00 13.33 13.06 13.20 12.62